To cure COVID-19, we propounded mopping viruses/infected cells by opposite-charges electrostatic attraction as mechanism of treatment. RNA viruses (including COVID-19 virus) are positively charged while DNA viruses an...To cure COVID-19, we propounded mopping viruses/infected cells by opposite-charges electrostatic attraction as mechanism of treatment. RNA viruses (including COVID-19 virus) are positively charged while DNA viruses and abnormal (infected/tumor) cells are negatively charged but normal cells are neutral. Molecules of Aluminum-magnesium silicate (AMS), a WHO- approved medicine, consist of Nanoparticles that have both negatively and positively charged ends. Ultra-small size (0.96 nm thick) of the Nanoparticles, allows them access to cells in all organs. Nigeria does not have natural AMS-deposits but she has Aluminum silicate and Magnesium silicate, abundantly. These solid minerals which are WHO-approved medicines too were used to formulate an AMS-brand, named, Medicinal synthetic AMS (MSAMS, VITUMED<sup>®</sup>, Antivirt<sup>®</sup>). Dextrose monohydrate (simple sugar) is incorporated in each MSAMS-formulation to convey the electrically charged Nanoparticles across mucous membranes (active-transportation) into blood for circulation to all organs. The Antivirt<sup>®</sup> has proved effective against all viral and abnormal-cell diseases so far tested including COVID-19.展开更多
<i>COVID</i>-19 <i>virus</i> has positive electrical charges. So, particles that are negatively charged would, by opposite charges-electrostatic attraction, inhibit its replication’s first sta...<i>COVID</i>-19 <i>virus</i> has positive electrical charges. So, particles that are negatively charged would, by opposite charges-electrostatic attraction, inhibit its replication’s first stage (attachment to cells) and mop its extra-cellular particles. Positively charged particles would similarly mop/destroy cells it infects because unlike healthy cells which are neutral, infected/tumor cells have negative electrical charges. <i>Nanoparticles</i> (0.96 nm) of Aluminum-magnesium silicate (AMS), WHO-approved medicine/adjuvant have both negative and positive charged ends. As adjuvant it improves antimicrobials’ efficacies (clearing secondary infections) while as silicate it enhances immunity. By inhibiting viral replication;mopping extra-cellular viruses/abnormal cells;clearing secondary infections;enhancing immunity, AMS terminates viral-infections/abnormal cells’ metastases. Natural AMS has impurities and its deposits are not found in Nigeria. So, Aluminum silicate and Magnesium silicate (WHO-approved medicines) were used for <i>Medicinal synthetic AMS</i> {MSAMS: Al<sub>4</sub> (SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub> (SiO<sub>4</sub>)<sub>3</sub>}. Since AMS is un-absorbable, dextrose monohydrate is incorporated in MSAMS-formulations to convey its <i>Nanoparticles</i> into blood for circulation to all organs/tissues (active-transportation). The MSAMS achieved quick cure (within 3 days) of all four COVID-19 patients used for its first-phase trial (one in Nigeria, two in Cameroon, one in Tanzania).展开更多
For clinical trial of Medicinal synthetic Aluminum-magnesium silicate (MSAMS, Antivirt<sup>®</sup>), on viral loads and CD4-lymphocytes counts of HIV/AIDS patients, 10 volunteers were treated. Thei...For clinical trial of Medicinal synthetic Aluminum-magnesium silicate (MSAMS, Antivirt<sup>®</sup>), on viral loads and CD4-lymphocytes counts of HIV/AIDS patients, 10 volunteers were treated. Their blood samples were tested for viral loads and for CD4-lymphocytes counts, before the treatment and every 4 weeks during the medication. The regimen was: MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immunace extra protection<sup>®</sup> (1 tablet/day), for 4 weeks. Then, it was reduced to 50 mg/kg (MSAMS) and the immune stimulant. When their viral loads become undetectable, they would be treated for additional 4 weeks. Initially, the Antivirt<sup>®</sup>-regimen appeared to worsen both HIV infection-load and immune deficiency but later relieved them. Patients’ mean-viral load increased (P = 0.020), from 1820.30 ± 868.75 to 2855.90 ± 960.98, after 4 weeks before reducing (P = 0.030) to 1565.20 ± 743.17, after 8 weeks. Similarly, their mean-CD4-lymphocytes count reduced (P = 0.008) from 496.80 ± 194.39 to 263.90 ± 149.26, after 4 weeks before improving (P = 0.001) to 507.90 ± 133.19, after 8 weeks.展开更多
HIV/AIDS patients were treated, daily, with MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immunace extra-protectionM<sup>?</sup> (1 tablet), for one month and then, with only MSA...HIV/AIDS patients were treated, daily, with MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immunace extra-protectionM<sup>?</sup> (1 tablet), for one month and then, with only MSAMS and the immune stimulants. They were tested, monthly, for viral loads and CD4- lymphocytes counts. Those whose viral loads became undetectable were tested for HIV confirmation (antigens/antibody). Their mean-viral load increased (P = 0.020) from 1820.30 ± 868.75 to 2855.90 ± 960.98 after first month, before reducing (P = 0.0.030) to: 1565.20 ± 743.17;759.20 ± 473.65;345.50 ± 115.01;192.80 ± 97.40;95.00 ± 55.80;37.40 ± 26.46;17.50 ± 16.88 (undetectable). Their mean-CD4 count was 496.80 ± 194.39 (lymphopenia). It reduced (P = 0.008) to 263.90 ± 149.26 after first month, before increasing (P = 0.001) to: 507.90 ± 133.19;692.70 ± 113.34;840.20 ± 139.41;1007.30 ± 163.50;1537.10 ± 302.10;1924.60 ± 247.45;2707.00 ± 837.87 (lymphocytosis). Patients whose viral loads became undetectable tested HIV-negative, one month after. CD4-lymphocytes count, approximating to zero-viral load, calculated from equation (Y = 2297.80 - 1.4731X) of line of best fit of graph of their viral loads onCD4-lymphocytes counts, was 1559.84/ml.展开更多
To reduce Chloroquine’s (CQ) side effects, so that increasing its duration for anti-Covid-19 trials could be safe, the drug was potentiated by stabilizing it with Medicinal synthetic Aluminum-magnesium silicate (MSAM...To reduce Chloroquine’s (CQ) side effects, so that increasing its duration for anti-Covid-19 trials could be safe, the drug was potentiated by stabilizing it with Medicinal synthetic Aluminum-magnesium silicate (MSAMS). CQ-treatment for five Plasmodium berghie-infected mice-groups were: 7 mg/kg (normal dose);7 mg/kg (CQ-MSAMS);7 mg/kg (CQ-MSAMS + B-vitamins), 5.25 mg/kg (CQ-MSAMS + B-vitamins) and the control. Means of parasitaemia, 42.00 ± 15.74 of the normal-dose group, 37.22 ± 11.88 of the 7 mg/kg (CQ-MSAMS) group and 33.57 ± 12.62 of the 7 mg/kg (CQ-MSAMS + B-vitamins) group showed no significant (P ≥ 0.05) reduction from 52.50 ± 11.99 of the control, but the 5.25 mg/kg (CQ-MSAMS + B-vitamins) dose, cleared (P ≤ 0.01) the parasiteamia (00.00 ± 00.00), showing that MSAMS-potentiated Chloroquine, has best efficacy at 75% of the recommended dose. Fever and anemia were absent at that 5.25 mg/kg, suggesting that lower doses of CQ have reduced side effects.展开更多
文摘To cure COVID-19, we propounded mopping viruses/infected cells by opposite-charges electrostatic attraction as mechanism of treatment. RNA viruses (including COVID-19 virus) are positively charged while DNA viruses and abnormal (infected/tumor) cells are negatively charged but normal cells are neutral. Molecules of Aluminum-magnesium silicate (AMS), a WHO- approved medicine, consist of Nanoparticles that have both negatively and positively charged ends. Ultra-small size (0.96 nm thick) of the Nanoparticles, allows them access to cells in all organs. Nigeria does not have natural AMS-deposits but she has Aluminum silicate and Magnesium silicate, abundantly. These solid minerals which are WHO-approved medicines too were used to formulate an AMS-brand, named, Medicinal synthetic AMS (MSAMS, VITUMED<sup>®</sup>, Antivirt<sup>®</sup>). Dextrose monohydrate (simple sugar) is incorporated in each MSAMS-formulation to convey the electrically charged Nanoparticles across mucous membranes (active-transportation) into blood for circulation to all organs. The Antivirt<sup>®</sup> has proved effective against all viral and abnormal-cell diseases so far tested including COVID-19.
文摘<i>COVID</i>-19 <i>virus</i> has positive electrical charges. So, particles that are negatively charged would, by opposite charges-electrostatic attraction, inhibit its replication’s first stage (attachment to cells) and mop its extra-cellular particles. Positively charged particles would similarly mop/destroy cells it infects because unlike healthy cells which are neutral, infected/tumor cells have negative electrical charges. <i>Nanoparticles</i> (0.96 nm) of Aluminum-magnesium silicate (AMS), WHO-approved medicine/adjuvant have both negative and positive charged ends. As adjuvant it improves antimicrobials’ efficacies (clearing secondary infections) while as silicate it enhances immunity. By inhibiting viral replication;mopping extra-cellular viruses/abnormal cells;clearing secondary infections;enhancing immunity, AMS terminates viral-infections/abnormal cells’ metastases. Natural AMS has impurities and its deposits are not found in Nigeria. So, Aluminum silicate and Magnesium silicate (WHO-approved medicines) were used for <i>Medicinal synthetic AMS</i> {MSAMS: Al<sub>4</sub> (SiO<sub>4</sub>)<sub>3</sub> + 3Mg<sub>2</sub>SiO<sub>4</sub> → 2Al<sub>2</sub>Mg<sub>3</sub> (SiO<sub>4</sub>)<sub>3</sub>}. Since AMS is un-absorbable, dextrose monohydrate is incorporated in MSAMS-formulations to convey its <i>Nanoparticles</i> into blood for circulation to all organs/tissues (active-transportation). The MSAMS achieved quick cure (within 3 days) of all four COVID-19 patients used for its first-phase trial (one in Nigeria, two in Cameroon, one in Tanzania).
文摘For clinical trial of Medicinal synthetic Aluminum-magnesium silicate (MSAMS, Antivirt<sup>®</sup>), on viral loads and CD4-lymphocytes counts of HIV/AIDS patients, 10 volunteers were treated. Their blood samples were tested for viral loads and for CD4-lymphocytes counts, before the treatment and every 4 weeks during the medication. The regimen was: MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immunace extra protection<sup>®</sup> (1 tablet/day), for 4 weeks. Then, it was reduced to 50 mg/kg (MSAMS) and the immune stimulant. When their viral loads become undetectable, they would be treated for additional 4 weeks. Initially, the Antivirt<sup>®</sup>-regimen appeared to worsen both HIV infection-load and immune deficiency but later relieved them. Patients’ mean-viral load increased (P = 0.020), from 1820.30 ± 868.75 to 2855.90 ± 960.98, after 4 weeks before reducing (P = 0.030) to 1565.20 ± 743.17, after 8 weeks. Similarly, their mean-CD4-lymphocytes count reduced (P = 0.008) from 496.80 ± 194.39 to 263.90 ± 149.26, after 4 weeks before improving (P = 0.001) to 507.90 ± 133.19, after 8 weeks.
文摘HIV/AIDS patients were treated, daily, with MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immunace extra-protectionM<sup>?</sup> (1 tablet), for one month and then, with only MSAMS and the immune stimulants. They were tested, monthly, for viral loads and CD4- lymphocytes counts. Those whose viral loads became undetectable were tested for HIV confirmation (antigens/antibody). Their mean-viral load increased (P = 0.020) from 1820.30 ± 868.75 to 2855.90 ± 960.98 after first month, before reducing (P = 0.0.030) to: 1565.20 ± 743.17;759.20 ± 473.65;345.50 ± 115.01;192.80 ± 97.40;95.00 ± 55.80;37.40 ± 26.46;17.50 ± 16.88 (undetectable). Their mean-CD4 count was 496.80 ± 194.39 (lymphopenia). It reduced (P = 0.008) to 263.90 ± 149.26 after first month, before increasing (P = 0.001) to: 507.90 ± 133.19;692.70 ± 113.34;840.20 ± 139.41;1007.30 ± 163.50;1537.10 ± 302.10;1924.60 ± 247.45;2707.00 ± 837.87 (lymphocytosis). Patients whose viral loads became undetectable tested HIV-negative, one month after. CD4-lymphocytes count, approximating to zero-viral load, calculated from equation (Y = 2297.80 - 1.4731X) of line of best fit of graph of their viral loads onCD4-lymphocytes counts, was 1559.84/ml.
文摘To reduce Chloroquine’s (CQ) side effects, so that increasing its duration for anti-Covid-19 trials could be safe, the drug was potentiated by stabilizing it with Medicinal synthetic Aluminum-magnesium silicate (MSAMS). CQ-treatment for five Plasmodium berghie-infected mice-groups were: 7 mg/kg (normal dose);7 mg/kg (CQ-MSAMS);7 mg/kg (CQ-MSAMS + B-vitamins), 5.25 mg/kg (CQ-MSAMS + B-vitamins) and the control. Means of parasitaemia, 42.00 ± 15.74 of the normal-dose group, 37.22 ± 11.88 of the 7 mg/kg (CQ-MSAMS) group and 33.57 ± 12.62 of the 7 mg/kg (CQ-MSAMS + B-vitamins) group showed no significant (P ≥ 0.05) reduction from 52.50 ± 11.99 of the control, but the 5.25 mg/kg (CQ-MSAMS + B-vitamins) dose, cleared (P ≤ 0.01) the parasiteamia (00.00 ± 00.00), showing that MSAMS-potentiated Chloroquine, has best efficacy at 75% of the recommended dose. Fever and anemia were absent at that 5.25 mg/kg, suggesting that lower doses of CQ have reduced side effects.